FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2088238988> ?p ?o ?g. }

• W2088238988 endingPage "333" @default.
• W2088238988 startingPage "327" @default.
• W2088238988 abstract "Pneumococcal vaccines based on conserved protein antigens have the potential to offer expanded protection against Streptococcus pneumoniae. This study examined the safety and immunogenicity in adults of three doses of a pneumococcal single-antigen protein vaccine candidate formulated with aluminum hydroxide adjuvant and recombinantly derived, highly detoxified, genetically mutated pneumolysin protein (PlyD1). This phase I, randomized, placebo-controlled, observer-blinded, dose-escalating study enrolled adults (18–50 years). In a pilot safety study, participants received a single injection of 10 μg PlyD1 and were observed for 24 h. Following review of the pilot safety data, participants were randomized (2:1) to receive two injections of PlyD1 at one of three doses or placebo 30 days apart. Assignment of second injection and successive dose cohorts was made after blinded safety reviews after each injection at each dose level. Safety endpoints included rates of solicited injection site reactions, solicited systemic reactions, unsolicited adverse events (AEs), serious AEs (SAEs), and safety laboratory tests. Immunogenicity endpoints included geometric mean concentrations of anti-PlyD1 IgG as determined by ELISA and functional assessment in an in vitro toxin neutralization assay. The study included a total of 100 participants, including 10 in the pilot study and 90 in the randomized study. None of the participants in the pilot study had SAEs, allergic reactions, or other safety concerns. Ninety participants received two doses of or placebo (n = 30) or active vaccine candidate at 10 (n = 20), 25 (n = 20), or 50 μg (n = 20). No vaccine-related SAE or discontinuation due to an AE occurred. Most solicited reactions were mild and transient. The most frequently reported solicited reactions were pain at the injection site and myalgia. Antigen-specific IgG levels and functional activity showed dose-related increases. When comparing the three dose levels, a plateau effect was observed at the 25 μg dose. All dose levels were safe and immunogenic. Repeat vaccination significantly increased the level of anti-PlyD1 antibodies. Functional antibody activity was demonstrated in sera from vaccinated individuals (ClinicalTrails.gov no. NCT01444352)." @default.
• W2088238988 created "2016-06-24" @default.
• W2088238988 creator A5001119457 @default.
• W2088238988 creator A5016691807 @default.
• W2088238988 creator A5020680319 @default.
• W2088238988 creator A5023596659 @default.
• W2088238988 creator A5052224707 @default.
• W2088238988 creator A5053083356 @default.
• W2088238988 creator A5053789462 @default.
• W2088238988 creator A5062272467 @default.
• W2088238988 creator A5070332174 @default.
• W2088238988 creator A5077232766 @default.
• W2088238988 date "2013-01-01" @default.
• W2088238988 modified "2023-10-12" @default.
• W2088238988 title "Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults" @default.
• W2088238988 cites W1487014480 @default.
• W2088238988 cites W1965772081 @default.
• W2088238988 cites W1977113996 @default.
• W2088238988 cites W1982472683 @default.
• W2088238988 cites W1988798435 @default.
• W2088238988 cites W1999684327 @default.
• W2088238988 cites W2000869034 @default.
• W2088238988 cites W2018126167 @default.
• W2088238988 cites W2024634994 @default.
• W2088238988 cites W2032871872 @default.
• W2088238988 cites W2033090269 @default.
• W2088238988 cites W2034197799 @default.
• W2088238988 cites W2038678671 @default.
• W2088238988 cites W2042287696 @default.
• W2088238988 cites W2050975734 @default.
• W2088238988 cites W2070186759 @default.
• W2088238988 cites W2077265445 @default.
• W2088238988 cites W2085780588 @default.
• W2088238988 cites W2087453197 @default.
• W2088238988 cites W2101284109 @default.
• W2088238988 cites W2106611720 @default.
• W2088238988 cites W2121832499 @default.
• W2088238988 cites W2126052291 @default.
• W2088238988 cites W2127574194 @default.
• W2088238988 cites W2131765138 @default.
• W2088238988 cites W2146272590 @default.
• W2088238988 cites W2147497766 @default.
• W2088238988 cites W2149128790 @default.
• W2088238988 cites W2149395493 @default.
• W2088238988 cites W2159323999 @default.
• W2088238988 cites W2159726435 @default.
• W2088238988 cites W2161519960 @default.
• W2088238988 cites W2168579739 @default.
• W2088238988 cites W2171486717 @default.
• W2088238988 cites W2172154969 @default.
• W2088238988 cites W2219768156 @default.
• W2088238988 doi "https://doi.org/10.1016/j.vaccine.2012.11.005" @default.
• W2088238988 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23153437" @default.
• W2088238988 hasPublicationYear "2013" @default.
• W2088238988 type Work @default.
• W2088238988 sameAs 2088238988 @default.
• W2088238988 citedByCount "82" @default.
• W2088238988 countsByYear W20882389882013 @default.
• W2088238988 countsByYear W20882389882014 @default.
• W2088238988 countsByYear W20882389882015 @default.
• W2088238988 countsByYear W20882389882016 @default.
• W2088238988 countsByYear W20882389882017 @default.
• W2088238988 countsByYear W20882389882018 @default.
• W2088238988 countsByYear W20882389882019 @default.
• W2088238988 countsByYear W20882389882020 @default.
• W2088238988 countsByYear W20882389882021 @default.
• W2088238988 countsByYear W20882389882022 @default.
• W2088238988 countsByYear W20882389882023 @default.
• W2088238988 crossrefType "journal-article" @default.
• W2088238988 hasAuthorship W2088238988A5001119457 @default.
• W2088238988 hasAuthorship W2088238988A5016691807 @default.
• W2088238988 hasAuthorship W2088238988A5020680319 @default.
• W2088238988 hasAuthorship W2088238988A5023596659 @default.
• W2088238988 hasAuthorship W2088238988A5052224707 @default.
• W2088238988 hasAuthorship W2088238988A5053083356 @default.
• W2088238988 hasAuthorship W2088238988A5053789462 @default.
• W2088238988 hasAuthorship W2088238988A5062272467 @default.
• W2088238988 hasAuthorship W2088238988A5070332174 @default.
• W2088238988 hasAuthorship W2088238988A5077232766 @default.
• W2088238988 hasConcept C126322002 @default.
• W2088238988 hasConcept C142724271 @default.
• W2088238988 hasConcept C147483822 @default.
• W2088238988 hasConcept C168563851 @default.
• W2088238988 hasConcept C197934379 @default.
• W2088238988 hasConcept C203014093 @default.
• W2088238988 hasConcept C204787440 @default.
• W2088238988 hasConcept C22070199 @default.
• W2088238988 hasConcept C27081682 @default.
• W2088238988 hasConcept C2776088486 @default.
• W2088238988 hasConcept C2777704310 @default.
• W2088238988 hasConcept C2777863537 @default.
• W2088238988 hasConcept C2778715236 @default.
• W2088238988 hasConcept C2780868878 @default.
• W2088238988 hasConcept C2781253189 @default.
• W2088238988 hasConcept C501593827 @default.
• W2088238988 hasConcept C71924100 @default.
• W2088238988 hasConcept C86803240 @default.
• W2088238988 hasConcept C89423630 @default.

• next